As an interesting side note, a proteasome inhibitor Bortezomib assists in the anti-cancer treatment via upregulation of HSP60 and HSP90 on the surface of cancer cells, facilitating cancer cell recognition by dendritic cells [170] (Table 5). This evidence concerns the gene HSP90AA1 and cancer.